HTG Molecular (NASDAQ:HTGM) is up 6.2% postmarket after announcing a new software product, HTG EdgeSeq Reveal.
It’s designed to streamline analysis of biomarket data from samples analyzed using the company’s EdgeSeq Precision Immuno-Oncology Panel.
The software enables applications including immunophenotyping of tumor infiltrating lymphocytes; monitoring of immunotherapy response biomarkers; and the elucidation of immune-escape mechanisms known to drive disease progression, the company says.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.